Inmune Bio Inc (INMB)

Jan 2, 2025, 8:52 AM EST - 15 days ago

INmune Bio: Phase 2 Trial In Alzheimer's Disease Is My Highest Risk-Reward Bet Of 2025

Dec 30, 2024, 3:20 PM EST - 18 days ago

INmune Bio: XPro Cognitive Readout In Sight, But Mind The Financial Dangers

Dec 4, 2024, 9:00 AM EST - 6 weeks ago

OmniScience Inc. and INmune Bio Inc. Partner to Accelerate a Phase 2 Alzheimer's Trial with Vivo, a Novel genAI Clinical Trial Control Tower

Oct 31, 2024, 8:09 PM EDT - 2 months ago

INmune Bio, Inc. (INMB) Q3 2024 Earnings Call Transcript

Oct 31, 2024, 4:05 PM EDT - 2 months ago

INmune Bio Inc. Announces Third Quarter 2024 Results and Provides Business Update

Oct 28, 2024, 8:00 AM EDT - 2 months ago

INmune Bio Inc. to Host Webinar on Cognitive Testing Using EMACC and CDR-SB

Oct 24, 2024, 3:03 PM EDT - 3 months ago

INmune Bio Inc. Announces Publication in Cell Reports Demonstrating XPro™ Promotes Remyelination

Oct 24, 2024, 9:30 AM EDT - 3 months ago

INmune Bio Inc. to Report Third Quarter 2024 Financial Results and Provide Corporate Update on October 31, 2024

Oct 11, 2024, 8:30 AM EDT - 3 months ago

INmune Bio Inc. to Participate in the Maxim Healthcare Virtual Summit

Sep 30, 2024, 5:04 AM EDT - 3 months ago

INmune Bio: NK Cell Therapy INKmune For mCRPC Is Another Shot On Goal

Sep 26, 2024, 8:00 AM EDT - 4 months ago

INKmune™ Demonstrates Excellent Safety and Increased NK-Cell Activity in First Dosing Cohort

Sep 17, 2024, 8:30 AM EDT - 4 months ago

INmune Bio Announces Results of Additional Blinded Interim Analysis of Phase 2 Alzheimer's Disease Trial Demonstrating Correlation between EMACC and CDR-SB Endpoints

Sep 13, 2024, 8:30 AM EDT - 4 months ago

INmune Bio Announces $13.0 Million Registered Direct Offering

Sep 3, 2024, 9:00 AM EDT - 4 months ago

INmune Bio Inc. to Present at the Baird 2024 Global Healthcare Conference

Aug 1, 2024, 11:50 PM EDT - 6 months ago

INmune Bio, Inc. (INMB) Q2 2024 Earnings Call Transcript

Aug 1, 2024, 4:05 PM EDT - 6 months ago

INmune Bio Inc. Announces Second Quarter 2024 Results and Provides Business Update

Jul 29, 2024, 9:00 AM EDT - 6 months ago

INmune Bio Inc. Announces New Phase 1 Study Data Demonstrating Dose-Dependent Effect of XPro™ on Proteins that Regulation Synapses in Alzheimer's Patients

Jul 25, 2024, 8:00 AM EDT - 6 months ago

INmune Bio Inc. to Report Second Quarter 2024 Financial Results and Provide a Corporate Update on Thursday, August 1, 2024

Jul 23, 2024, 8:45 AM EDT - 6 months ago

INmune Bio Inc. Publishes Novel Biology on Natural Killer Cancer Immunotherapy INKmune™ in the Journal for ImmunoTherapy of Cancer

Jul 8, 2024, 6:12 AM EDT - 6 months ago

INmune Bio: Promising Phase 2 Trials For Alzheimer's Drug XPro

Jul 5, 2024, 9:57 AM EDT - 7 months ago

INmune Bio: Still A Bargain If Their Alzheimer's Program Reaches Its Inflection

May 30, 2024, 8:00 AM EDT - 8 months ago

INmune Bio Inc. to Join Russell 3000® Index

May 11, 2024, 8:58 PM EDT - 8 months ago

INmune Bio, Inc. (INMB) Q1 2024 Earnings Call Transcript

May 9, 2024, 4:05 PM EDT - 9 months ago

INmune Bio Inc. Announces First Quarter 2024 Results and Provides Business Update

May 7, 2024, 8:00 AM EDT - 9 months ago

INmune Bio Inc. to Report First Quarter 2024 Financial Results and Provide a Corporate Update on Thursday, May 9

Apr 30, 2024, 8:00 AM EDT - 9 months ago

INmune Bio Inc. Provides Update on Two Patients from the Phase 1b Alzheimer's Disease Trial who Continue to Receive XPro™ Under Compassionate Use for Over Three Years

Apr 29, 2024, 8:00 AM EDT - 9 months ago

INmune Bio Inc. Completes First Cohort and Initiates Second Cohort of Phase 1/2 Study of INKmune™ Natural Killer Cell Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer

Apr 25, 2024, 9:00 AM EDT - 9 months ago

INmune Bio Inc. Announces $9.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Apr 23, 2024, 8:00 AM EDT - 9 months ago

INmune Bio Inc. Announces 24-Month Stability Validation of XPro™ for Phase III Readiness and Commercial Supply Chain Modeling & Development of Novel Immunogenicity Assay

Apr 22, 2024, 8:00 AM EDT - 9 months ago

INmune Bio Inc. Raises Approximately $4.8 Million in Gross Proceeds Through Registered Direct Offering with Officers, Employees and Directors Purchasing Approximately 20% of the Offering

Apr 22, 2024, 4:27 AM EDT - 9 months ago

INmune Bio: An Opportunity In The Freefall (Rating Upgrade)

Apr 8, 2024, 8:00 AM EDT - 10 months ago

INmune Bio Inc. Presents Data on INB03's Role as an Immune Check Point Modulator in the Treatment of High-Risk Breast Cancer at AACR 2024

Mar 28, 2024, 8:18 PM EDT - 10 months ago

INmune Bio, Inc. (INMB) Q4 2023 Earnings Call Transcript

Mar 28, 2024, 4:01 PM EDT - 10 months ago

INmune Bio Inc. Announces Year End 2023 Results and Provides a Q4 Business Update

Mar 26, 2024, 4:01 PM EDT - 10 months ago

INmune Bio Inc. to Report Fourth Quarter 2023 Financial Results and Provide a Corporate Update on Thursday, March 28

Mar 13, 2024, 8:00 AM EDT - 11 months ago

INmune Bio CSO and Co-Founder Mark Lowdell, Ph.D. Receives The ISCT Career Achievement Award in Cell and Gene Therapy

Mar 5, 2024, 8:00 AM EST - 11 months ago

INmune Bio Reports Significant EEG Improvement in Alzheimer's Patients Treated with XPro™

Feb 12, 2024, 9:00 AM EST - 1 year ago

INmune Bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Feb 6, 2024, 9:00 AM EST - 1 year ago

INmune Bio to Participate in Baird's Biotech Discovery Series Webcast on February 13, 2024

Jan 30, 2024, 8:00 AM EST - 1 year ago

INmune Bio Announces FDA Removal of Clinical Hold for Alzheimer's Disease Program

Jan 2, 2024, 8:00 AM EST - 1 year ago

INmune Bio Announces First Patient Dosed in a Phase 1/2 Study of INKmune™ in Patients with Metastatic Castration-Resistant Prostate Cancer

Dec 18, 2023, 4:01 PM EST - 1 year ago

INmune Bio Provides Update Regarding Global Alzheimer's Phase II Clinical Trial and Clinical Hold Issued by the United States FDA

Dec 5, 2023, 3:58 AM EST - 1 year ago

Alzheimer's Disease Drug Development: Another Lost Year

ANVS AVXL BIIB LLY SAVA

Nov 29, 2023, 8:00 AM EST - 1 year ago

INmune Bio Inc. Demonstrates that INB03 Enhances the Uptake of Trastuzumab Deruxtecan in HER2+ Breast Cancer with MUC4 Expression in Poster Presented at San Antonio Breast Cancer Symposium

Nov 27, 2023, 8:00 AM EST - 1 year ago

INmune Bio Receives EMA's Authorization in France and Spain for Phase II Clinical Trial of XPro™ for Early Alzheimer's Disease

Nov 15, 2023, 9:00 AM EST - 1 year ago

INmune Bio Inc. Announces Expansion of Phase II Clinical Trial for Alzheimer's Disease in Europe

Nov 1, 2023, 10:38 PM EDT - 1 year ago

INmune Bio, Inc. (INMB) Q3 2023 Earnings Call Transcript

Nov 1, 2023, 4:10 PM EDT - 1 year ago

INmune Bio Inc. Announces Third Quarter 2023 Results and Provides Business Update

Oct 31, 2023, 8:00 AM EDT - 1 year ago

INmune Bio Inc. Patent Claims Covering INB16 Cell Line and INKmune™ Therapeutic Composition given Favorable Patentability Opinion by International Search Authority

Oct 30, 2023, 9:07 AM EDT - 1 year ago

INmune Bio Inc. Presents Preclinical Data at SITC 2023 Showing INB03 is an Innate Immune Check Point Inhibitor that Downregulates SIRPα